Pertuzumab: The New Kid on “HER” Block

Approximately 20% of all breast cancers are caused by the oncogenic human epidermal growth factor receptor 2 (HER2) and although trastuzumab has led to significant improvements in treating HER2-positive breast cancers, many patients develop… [Learn More…]

S-1: A Synergistic Drug Combination that Improves Overall Survival in Patients with Stage II and III Gastric Cancer

S-1 (TS-1) is a chemotherapeutic preparation combining tegafur, gimeracil and oteracil potassium in a molar ratio of 1:0.4:1 that significantly improves overall survival in patients with stage II or III gastric cancer. In this study, patients that… [Learn More…]

NovoTTF-100A Provides Non-invasive Treatment Options for Recurrent Glioblastomas

The NovoTTF-100A system is a portable, non-invasive medical device that slows and reverses tumor growth by creating low intensity, alternating electric fields within the tumor. In this study, continuous NovoTTF-100A monotherapy (20-24 hours per day,… [Learn More…]

Everolimus and Exemestane for Postmenopausal Women with Letrozole or Anastrozole-Resistant Breast Cancers

Everolimus is a drug that targets the mTOR pathway, which is over-activated in many cancers and associated with resistant to hormonal therapy in breast cancers. In this study, everolimus was used in combination with exemestane to treat… [Learn More…]

Positive Phase II Data Support Entinostat Treatment for Advanced Breast Cancer

Entinostat is an inhibitor of class I histone deacetylase, an enzyme involved in epigenetic gene regulation commonly altered in cancers. Importantly, doctors can perform a simple test to determine whether or not entinostat will be effective in a… [Learn More…]

Rindopepimut Significantly Increases Overall Survival of Treatment-Resistant Glioblastoma Patients

Rindopepimut is a vaccine that targets the epidermal growth factor receptor variant III mutation (EGFRvIII), which occurs in 31% of glioblastoma multiforme cases and is linked to poor long-term survival regardless of other factors such as extent of… [Learn More…]

New Treatment Extends Life for Men with Advanced Prostate Cancer

Most patients with advanced prostate cancer eventually become resistant to anti-androgen therapy (including bicalutamide therapy). MDV3100 is an advanced drug that blocks multiple processes of androgen signalling including binding of testosterone to… [Learn More…]

Why All Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Should Have Their Tumors Tested for EGFR and ALK Abnormalities

The anaplastic lymphoma kinase (ALK) fusion oncogene and the epidermal growth factor receptor (EGFR) represent molecular targets in a subset of non-small cell lung cancers (NSCLCs). NSCLC accounts for nearly 85 % of all lung cancers with 7 % of… [Learn More…]

Resveratrol (SRT501) Increases Apoptosis of Liver Metastasis in Patients with Colorectal Cancer

SRT501 is a micronized formulation of resveratrol that has significantly increased oral bioavailability. In this study, patients with colorectal cancer and hepatic metastases scheduled to undergo hepatectomy were given SRT501 prior to surgery…. [Learn More…]

Concurrent Chemo-Radiation During Primary Treatment Reduces Recurrence Due to Micro-Metastasis

It is well accepted that micro-metastasis of the primary tumor is responsible for disease recurrence and metastasis. However, by the time most primary tumors are detected using standard diagnostic assays, distant micro-metastasis has likely occurred… [Learn More…]